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Abstract
Mathematical modeling in cancer has been growing in popularity and impact since its inception in
1932. The first theoretical mathematical modeling in cancer research was focused on understanding
tumor growth laws and has grown to include the competition between healthy and normal tissue,
carcinogenesis, therapy and metastasis. It is the latter topic, metastasis, on which we will focus this
short review, specifically discussing various computational and mathematical models of different
portions of the metastatic process, including: the emergence of the metastatic phenotype, the timing
and size distribution of metastases, the factors that influence the dormancy of micrometastases and
patterns of spread from a given primary tumor.
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Introduction: Why use mathematical models?
Metastasis accounts for 90% of cancer related deaths [1], and the shift from localized to metastatic
disease represents a paradigm shift for clinicians and patients alike as the strategy for therapy
changes from aggressive and localized, to systemic and generally palliative. Despite its importance,
this complex multi-step process remains poorly understood. With the exception of studies show-
ing genetic correlations between primary sites and sites of metastatic arrest [2, 3], there is little
understanding of the driving principles behind this process. Our lack of knowledge is for example,
reflected in the fact that self-seeding, a process whereby a primary tumor releases metastatic cells
that return to the primary tumor and accelerate its growth, is hypothesized to be a driver of pri-
mary growth [4], yet our current knowledge of the metastatic cascade is insufficient to determine the
validity of this claim. For such a multi-faceted process, only through a combination of experimental
and theoretical investigations can we hope to gain a comprehensive mechanistic understanding, and
therefore uncover sensitive points where we can intervene and prolong the life of affected patients.
The strength of experimental model systems is their ability to provide clear answers to specific
questions. The strength of mathematical models is their ability to combine disparate experimental
data and coalesce them into a coherent framework, which can then be used to predict the overall
dynamics of the system in question. In particular, mathematical models allow for identification
of the parameters to which the system is the most sensitive, and also allow for logical reasoning
beyond what experiments can provide. In this sense, mathematical models of metastasis should be
playing a larger role in the research in this area as experimentation is typically limited to one or a
few steps in the cascade. Many mathematical models to date, however, have also concentrated on
only a subset of the steps of the cascade. While these models are useful, as they have quantified
the impact of parameters within the models of each step, they have yet to yield any fundamental
additions to our knowledge of the process itself.
Mathematical models of biological systems tend to fall into two broad camps: descriptive and
mechanistic. Both approaches can provide useful insights but since we want to connect directly
with experimental measurement and drive novel experimentation, mechanistic models are where we
need to focus our attention. This doesn’t mean that we should build all encompassing mechanistic
models of every process that we think is important in metastasis - since this would only provide us
with a complex caricature of the real system with no additional understanding. Instead, we need to
consider key processes and describe them in a level sufficient to gain insight, which should be tied
to the resolution of the experimental data that might be used to drive and validate such models in
the first place. Mirroring experimental observation should always be a key part of model validation
but ultimately if a model is to be useful it should also make predictions that go beyond current
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Figure 1: An overview of the metastatic process. Each step in the cascade represents an opportunity
for experimental systems to be designed. Understanding the temporal dynamics within each step,
and how the steps join together, however, is a challenge that also requires mathematical modeling.
Cells from typically heterogeneous primary tumors grow (A) and some (blue and purple) are able
to intravasate (B). Once in the vascular system, cells are subject to physical forces and selection
of flow and filtration (C) until they extravasate (D) and colonise a foreign tissue bed (E). tumors
at this final stage will be distributed in size based on temporal and other factors (F) and will be
made up of only certain clones from the primary tumor dependent on biological factors.
observations, and further drive our understanding and inquiry.
To this end, our group, and others, have begun to build models more like those typically built
to understand complex engineering systems, into which the more detailed models can eventually be
embedded when the time comes for specific predictions to be made. Until that time, these higher
level models serve to shed light on areas of our knowledge which are most severely lacking, and
provide experimental questions to fill those gaps in a systematic manner.
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Figure 2: An overview of the scientific method, and where theoretical/computational scientists
fit into this process in the life/medical sciences and biology. Theoretical biology is the science of
putting together existing knowledge into specific theoretical frameworks which can be used to make
predictions and generate further hypotheses. Bioinformatics is a statistical science used for helping
scientists make conclusions when faced with large data sets and non-linear relationships. Dialogue
between multi-disciplinary scientists helps shape meaningful experiments. Laboratory technique
translates experimental constructs into meaningful results.
Where experiments cannot go: opportunities for mathematical mod-
els
To definitively answer questions in biology, the burden of proof falls on the experimental scientists.
To connect the disparate experimental ‘truths’ into a coherent framework however, is the purview of
theorists. Further, when theory has been established, but necessary experimental techniques have
yet to be developed, theory can again step in to advance science by making specifically testable
predictions - vastly shrinking the set of possible experiments. This dual role is best understood by
thinking of where mathematical/computational science fits into the scientific method. The place
of theory, typically called mathematical or theoretical biology, lies between biological conclusions
and new hypotheses (Figure 2). The central goal of this discipline is to create rigorous frameworks,
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beyond linear ‘cartoon’ models of mechanism, through which specific predictions and hypotheses
can be generated. Bioinformatics, another computational field in biology, largely works between
experiment and conclusion, helping to make sense of the vast amounts of data that come out of
modern day experiments. This review will focus on models from the field of theoretical biology.
A note on mathematical tools: stochastic vs. deterministic models
Like experimentalists, mathematical modelers have many tools at their disposal. These tools com-
prise a wide spectrum, ranging from classical ‘pen and paper’ models, to those requiring powerful
computers to iterate, and everything in between. There are many ways to distinguish these models
from each other, but likely the most telling dichotomy is the difference between stochastic and
deterministic models.
A deterministic model is one in which there is no randomness: the model will behave exactly
the same way each time it is solved. This does not mean that the model is necessarily predictable:
indeed, many deterministic models exhibit wild fluctuations and even chaotic results, exhibiting
strong dependence on even small changes in initial conditions or parameter values. The strength
of these models is that they allow us to understand all the possible behaviors of a system and in
which parameter regimes those behaviors occur. Examples of deterministic models discussed in
this review include ordinary and partial differential equations (ODEs and PDEs) which describe
how key quantities of interest, such as chemical concentrations or cell densities, vary continuously
with one (in the case of ODEs) or many (for PDEs) independent variables. Well mixed systems,
where space is not considered, are typically modeled with ODEs where the dependent variables
evolve in time; PDEs are utilized when there is also spatial heterogeneity, or differences in ‘age’ or
differentiation status across the population modeled.
A stochastic model, on the other hand, has randomness written in to the system itself. This
randomness can be incorporated into the model in many different ways. Models can represent many
individual entities which can interact with one another or move in ways defined by probabilities.
Alternatively, noise terms may be explicitly incorporated into existing deterministic descriptions.
As compared to their deterministic counterparts, these sorts of models often are better represen-
tations of the underlying biological processes, which do seem to be governed at some level by
randomness, and the results of any given simulation of a model can be quite different from an-
other, again mimicking biology. Gaining a deep understanding of these models through analysis
however, is usually much more difficult, and we must often rely upon averages of many realisations
to gain an understanding of the system, or on analysing the average (”mean-field”) behavior of the
system, effectively returning to a deterministic description. Examples of the types of stochastic
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model discussed in this review include Markov chains (MCs), cellular automata (CAs) and Moran
processes. MCs are stochastic processes in which a population is subject to a time-independent
series of transitions, from one state to another in a ‘memoryless’ fashion, that is without regard to
the history of the system [5]. CAs are a discrete time and discrete ‘cell’ based models. Individual
cells, often called ‘agents’, are programmed with simple rules and simulated as they interact in
a computational domain. Complex behaviors often can emerge from simple rule sets and limited
numbers of agents [6], and while these models are not necessarily stochastic by nature, the ones
described in this review are, by virtue of their rules. The Moran process [7] is a stochastic process
of birth and death in which a mixed population of two (or more) species compete in a manner
meant to mimic Darwinian selection.
In the science of metastasis, all of these model types have been, and will continue to be,
utilized for different applications. This is particularly relevant as there are a number of steps in the
metastatic cascade (outlined in Figure 1) which span multiple scales, both spatial and temporal.
In the remainder of this brief review, we will cover the most relevant mathematical models of the
metastatic cascade and highlight the ways in which these models have affected our knowledge, future
experiments and clinical decision making. We will begin by describing a series of mathematical
models built around a specific experimental murine metastasis model which was able to give insight
into several key, unmeasurable parameters. We will then describe a series of models focussed on
the genetic emergence of metastasis which generates a number of hypotheses, but can not yet be
tied to experimental data. We then discuss models aimed at understanding the size distribution of
metastasis at the time of diagnosis, several of which offer the possibility of connecting to patient-
specific data. We then review several models aimed at understanding the temporal patterns of
recurrence through the dormancy mechanism, and we conclude by reviewing some recent network
models of metastasis aimed at understanding the anatomic patterns of metastatic spread within
the body.
Models of experimental systems
One of the first attempts to model the metastatic process is described in a series of papers by Liotta
and colleagues [8, 9, 10]. In this work, the authors built an experimental system and mathematical
models in parallel in an attempt to better define the parameters of each step in the process. The
experimental system considered was a mouse model of fibrosarcoma that readily formed pulmonary
metastases, via both implantation and intravenous injection. In this way, the authors were able to
accurately control many parameters, and use the results to obtain estimates for those that could
not be measured directly.
7
Tumour 
cells in 
primary
Vascular 
surface 
area of 
primary
Invading 
cells within 
vessel wall
Cells 
arrested in 
end organ 
vessels
Metastatic 
foci
Angiogenic 
factor
Nutrient 
availability CTC flow
Colony 
formationintravasation 
Figure 3: Compartment model developed by Saidel et al. [8] Each of the blue boxes represent
measurable quantities from the in vivo model, while the ovals represent quantities inferred from
the model.
The authors derived an ODE model to describe how the population of tumor cells changes in
time in each of several key ‘compartments’ as a result of flux between them. Each of the compart-
ments in their mathematical model represents a discrete phase of the metastatic cascade, illustrated
schematically by the blue boxes in Figure (3) [8]. Numbers of cells measured from the murine ex-
perimental system were used to parameterize this mathematical model. The model was then used
to predict the effect of a number of perturbations to the system including: tumor resection, tumor
trauma, vessel growth inhibition, lung vessel damage and inhibition of intravasation. Each of these
perturbations was simulated to predict response and the experimental system was then assayed
with good correlation, giving significant insight into the otherwise unmeasurable aspects of the
system and the mechanisms driving the response to the perturbations.
As discussed previously, biological systems are often ruled by stochastic processes at the cellular
level, and in the case of metastasis, this is certainly the case. To this end, Liotta et al. developed
and analysed a MC model of a subset of the above system [9]. The authors additionally considered
that cancer cells do not only travel and arrest as single cells, but are found in clumps of varying
size [11]. The model contains three compartments: tumor cell clumps in the circulation, tumor cell
clumps arrested in the pulmonary capillary bed, and pulmonary metastatic foci. In agreement with
experimental data, the model assumes that the entry rate of clumps is size-dependent, following a
decaying power-law (i.e. the number of clumps of size n scales as n−α, α = 2), that the clump death
rate is inversely proportional to size, and the colonisation rate increases linearly with clump size.
The validation was carried out in the fibrosarcoma mouse model, where cancer cells were injected
intravenously and the animals were sacrificed 10-30 days post-implant. The model showed good
agreement both with respect to the number of macroscopic metastatic foci as a function of time,
and the time-dependent probability of finding a metastasis-free animal. An interesting conclusion
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from the study was that larger clumps have a strong impact on metastasis formation, and hence
that disassociating agents that reduce clump size could have therapeutic effect.
A follow-up study further simplified this mathematical model to account only for arrest and foci
formation, without regard to clump size [10]. Interestingly, the sharp transition in the metastasis-
free probability remained, suggesting that this phenomenon is due only to the stochastic nature
of arrest and foci formation. If these results can be extended to patients they could represent a
novel method for assessing the likelihood of micrometastatic lesions that eventually could become
clinically relevant.
Models as abstractions: insights into unmeasurable processes
In the previously discussed models, each portion of the model corresponded directly to an aspect
of an experimental system. In this way, the authors were able to use the strength of each system to
gain a deeper understanding of the mechanisms driving each portion of the well-controlled process.
Many aspects of the metastatic process in the clinic, however, are not amenable to this sort of
methodology, and cannot be measured/quantified directly. This situation, where measurements
are not yet able to be made, is one where mathematical models can play an influential role and
relieve the impasse at which we would otherwise be. A specific case of this is in tumor genomics: we
know that genetic mutations play a role, but we are not yet able to measure the dynamic changes
of a tumor genome within a patient over time.
Evolutionary models: emergence of metastatic clones
The emergence of metastatic disease has largely been attributed to cells gaining functions specific
to intravasation (Figure 1 B). This gain of function has been linked to genetic mutation, with large
numbers of specific genes being implicated. More generally, the epithelial-mesenchymal transition
(EMT) has been identified as a process (likely polygenic) involved in the acquisition of metastatic
potential [12].
Experimental studies have shown that EMT (among other phenotypic changes) is important
for the development of metastatic clones [13], but as measuring the individual mutations within
a patient’s tumor over time remains beyond the scope of experimental science, understanding the
dynamics of this process is a ripe question for theoreticians. To this end, a number of models have
employed a stochastic description called the Moran process [7] to study the genetic landscape of
a tumor’s cellular population over time. In this process, populations of constant size consisting of
individual agents (cells), usually of two distinct (geno)types, are grown in competition with one
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another under selection. The Moran process was originally designed to mimic Darwinian selection,
where cells of a given type are chosen randomly to divide or die based on an ascribed fitness, usually
linked to division rate. The population dynamics are then simulated, with the aim of understanding
long-term behavior (coexistence or dominance by one population). These models serve as excellent
platforms through which to understand the emergence of new clones within a population, much
like the emergence of EMT, or any other metastasis-specific trait.
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Figure 4: The Moran process as utilized to study the emergence of metastasis [14, 15, 16]. The
primary tumor (left) is allowed to grow and turn over, the population changing based on the
probability of mutation, u, and the relative fitness of the two cell types, r0 and r1. As cells gain
the ability to metastasize (mutate into type 1 cells) they also have the opportunity, at rate q, to
be exported and begin their own colonies. At steady state, the primary tumor can be composed
of either all type 1 cells (dominance, when r1 > r0) or a coexistence with the proportions of cells
governed by the mutation u and the fitness ratio r1/r0.
To study the dynamics of the emergence of the metastatic phenotype, Michor et al. [14] proposed
a model of tumor growth, based on the Moran process, that took account of mutation to a metastatic
phenotype. The authors modeled a heterogeneous tumor made up initially of cells without the
ability to metastasize (type-0, fitness r0). At each time step, a cell is randomly chosen to divide
10
(biased by fitness) at which time the cell has a probability u of producing mutated offspring that
can metastasize (a type-1 cell) with fitness r1 (where a fitness of 1 is neutral). This mutated
offspring also now has a probability q of being ‘exported’ from the population to initiate a metastatic
tumor of their own (Figure 4). Results for a range of parameter combinations were calculated
both analytically and by exact stochastic simulation. The authors found that initiating tumors
with different parameter combinations could lead to qualitatively different outcomes: the model
predicted that metastatic clones are most likely the result of advantageous mutations that will
occupy the majority of the primary tumor. Indeed, for a mutation that confers metastatic potential
and simultaneously a lower fitness in the primary tumor, there must be approximately a million-fold
increase in metastatic potential for it to generate the same number of metastases in a patient.
Dingli et al. [15] extended the previous model by Michor et al. [14] by allowing tumors to grow
above a constant size, and incorporating a dependence on tumor size in the export probability. The
authors suggested that certain types of mutations confer a fitness advantage (r1 > 1) and metastatic
ability (e.g. mutations in RAS and MYC), and can dominate the tumor and seed many metastases;
while other types of mutations (such as MSG) have a lower relative fitness as compared to non-
mutants (r1 < 1) and can therefore co-exist only in small populations and can even be ‘exported’
entirely, depending on the export rate (q). This insight provides an explanation for the situation
in which there exists metastatic disease without evidence for cells with metastatic potential in the
primary, or in the more extreme case where there is no evidence of a primary tumor at all [17].
To consider this model in a more clinically grounded context, Haeno and colleagues [16] studied
a new metric, total tumor burden, which they tied to survival. In this study, the aforementioned
model was extended and the timing of interventions, which included surgery (removal of a fraction
of type-0 and type-1 cells; those residing in the primary tumor) and chemotherapy (affecting birth
and death rates for all cells) was incorporated. The authors used threshold values for total tumor
burden to correlate with time of diagnosis and patient death and investigated the effect of each
of the therapies. They found that, depending on how a simulated patient’s tumor was situated
in parameter space (the relative rates of acquisition of the metastatic phenotype, u, ‘export’ of
the metastatic cells to foreign stroma, q, and the birth-death balance (r0,r1) of each cell type),
qualitatively different outcomes could be obtained from therapies given at different times. While
currently beyond our abilities to tie to clinical data, this model served to illustrate how such
a technique could shed light on the metastatic processes in play for a patient, and potentially
influence treatment choice.
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Metastatic colony size distribution
At present there is a single designation in the standard clinical cancer staging system (the TNM
system, which describes the primary Tumour, any positive lymph Nodes and any Metastasis) to
describe metastatic disease: either M0 for a patient with no observable metastasis, or M1 for
a patient with any amount of metastatic disease; yet there can be great variation in both size
and location of metastases from one patient to another. Historically, patients with any amount of
metastatic disease have only been offered localized treatment at those metastatic sites if they caused
a specific problem, but not with curative intent (with several specific exceptions, e.g. solitary brain
metastasis in lung cancer). This paradigm is beginning to change with the advent of the concept
of ‘oligometastasis’ describing the situation where a patient may have only a small number of
metastases, a number worth treating. While only a small number of trials have been conducted
[18, 19], this approach is gaining in popularity with the increased availability of highly targeted,
minimally invasive therapeutic modalities such as stereotactic body radiation therapy. The main
problem confronting this movement, however, is our lack of understanding of which situations
represent ‘oligometastasis’. That is, which patient with one obvious metastatic lesion actually
has many other, subclinical ones, and which does not? To answer this question, a number of
mathematical models have been developed in an attempt to understand the distribution of sizes of
metastatic lesions in time.
One such study is that of Iwata et al. [20], in which computed tomography (CT) images of
spatially separated colonies of hepatocellular carcinoma in a patient’s liver were fit to a novel PDE
model of colony size. In their system the population of tumors was modeled as a distribution of
colony size over time. Each colony was assumed to grow by a saturating growth function (specifically
Gompertzian growth, though any growth law could have been used [21]) and release metastatic cells
at a rate proportional to the volume of the colony raised to some power, effectively representing
the fractal dimension of the blood supply of the tumor [22, 23].
Using three successive scans of the patient’s tumor progression without therapy, and several after
initiation of chemotherapy, the model parameters were fit and predictions about the pre-diagnosis
time course could be made. Further, and likely of greater import, predictions about subclinical
metastatic burden at the time of diagnosis were made. This sort of information, which is currently
not available to clinicians, represents a class of personalized information about a patient’s disease
that does not rely on genomic information, and could be measured for any patient who already
has scans taken during the course of standard therapy. This approach, of using scans which are
‘standard of care’, is being utilized in primary glioblastoma and is approaching clinical trials [24],
but the model of Iwata et al. represents the only such attempt, to our knowledge, in metastatic
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disease.
The same question that was addressed with a deterministic model by Iwata et al. [20] has been
addressed using a number of stochastic modeling techniques. Bortoszyinski et al. [25], Hanin et
al. [26] and Xu et al. [27] used similar growth laws as discussed by Iwata et al. and then derived
expressions called joint distribution functions, which predicted the probability of there being a
given distribution of metastatic colony sizes at a given time. The authors then each validated their
models against a single patient’s data. The models, after fitting, were also able to predict several
salient features about the patients’ pre-diagnosis condition and the natural history of their disease.
Understanding temporal recurrence patterns
Tumor dormancy
The mechanisms and timing of distant recurrence of cancers after treatment of the primary tumor
remain difficult to study in the clinic. It is widely believed that most patients have sub-clinical
micrometastatic disease at the time of diagnosis, the distribution of which we discussed in the
previous section, but that only some of them will go on to develop overt metastasis. The reasons
for this are largely unknown even though there is a large literature [28], both experimental and
theoretical, surrounding the period of so-called ‘tumor dormancy’.
After definitive therapy for most primary cancers, the majority of distant recurrences occur in
the first two years, mostly due to micrometastatic disease that was undetected at the time of primary
therapy that eventually grew to a detectable size. Demicheli and colleagues [29] however, noted a
bimodal distribution of relapse times for patients treated in the Milan trial of primary surgery for
breast cancer. One peak was in the expected range, at 18 months, while the other was a broader
peak centered at 60 months after surgery. To understand this long lag time, Retsky, Demicheli
and colleagues [30, 31] proposed a new mechanism of cancer dormancy and recurrence. They
posited that micrometastases that exist at the time of surgery can be activated by the subsequent
inflammation into a non-dormant state. To illustrate their hypothesis they built a stochastic model
of micrometastasis dormancy in which metastatic sites exist in one of three states: dormant single
cells, colonies arrested at the avascular limit, and growing colonies. In their simulations they allowed
for stochastic transitions between these states (assuming the transition was to a larger state) and
showed that this model could recapitulate the unexpected bimodal distribution of the large clinical
trial - but only if they allowed for a transition ‘bonus’ added at the time of surgery (Figure 5).
Their results have been used to argue for differing chemotherapy schedules as well as suppression
of inflammation at the time of primary surgery [32, 33].
Another explanation for variable dormancy times is related to the cancer stem cell hypothesis.
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Figure 5: The model posited by Retsky et al. [30]. The primary tumor (red) is allowed to grow and
randomly seed single metastatic cells. The single cells can switch state stochastically to become
growing colonies which are constrained by an avascular limit (P1,2) or which are vascularized (P1,3).
In order to fit the results of this model to bimodal recurrence pattern of the Milan trial [29], they
needed to effect a ‘bonus’ to the transition probabilities at the time of surgery (S), which led to
the hypothesis that there is a metastasis promoting role by peri-surgical inflammation.
This well-known hypothesis has been modeled extensively for a number of different tumors (for a
review, see Michor [34]), but has only received limited attention in connection to dormancy and
metastasis. Enderling and colleagues pioneered this work and showed, using a stochastic model
of cellular hierarchy within a tumor, that single cancer stem cell-driven solid microtumors may
undergo long periods of dormancy despite cellular activity [35]. The length of the dormancy period
depends on the complex interplay between stem cells and their non-stem cancer cell counterparts.
Specifically, they found that impaired cancer stem cell migration, as well as large numbers of non-
stem cancer cells, increase population dormancy times. Higher non-stem cancer cell death rates
were correlated with shorter dormancy times and, paradoxically, with increased tumor growth in
the long term [35, 36, 37]. This ‘tumor growth paradox’ was also explored in an analytical model
by Hillen et al. [38] and was put forward as an explanation for some of the failures of therapy [39].
Primary-secondary communication
The idea that primary tumor factors can affect the growth of metastases has also been modeled
by considering communication between the primary tumor and secondary metastatic deposits.
Boushaba and colleagues [40, 41] considered an anti-angiogenic factor secreted by the primary
which would keep spatially separated, yet local, metastases in a dormant state and reported a critical
distance window in which this effect was active. This result is difficult to interpret in hematogenous
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metastasis as the idea of a diffusion ‘distance’ for any factor secreted by the primary is not trivially
understood because of the fluid dynamics involved in blood flow as compared to diffusion through
tissue. A different study, by Eikenberry et al. [42], considered the effect of the primary on metastatic
deposits through interactions mediated by the immune system. They modeled the removal of the
primary as a decrease in immune stimulus, which in turn could promote metastatic growth. A
mechanism-agnostic model analyzed by Diego et al. showed primary-secondary communication
to have an effect on metastatic growth, but only in a very small region of parameter space [43],
suggesting that, while possible, this is a rare phenomenon. While there is a growing theoretical
literature on this subject, the clinical data to support its import are lacking and the data in
biological model systems have been shown in only a few studies, reviewed by Peeters et al. [44],
and therefore it is difficult to draw any solid conclusions at this time.
Making sense of existing data
We have now discussed mathematical models built with specific experimental systems in mind, ones
designed to help explain some unmeasurable quantities in existing patients and ones for which no
experiments can yet be done. The final class of models that we will discuss were derived in order
to analyze existing, population level data of metastatic spread, with the aim of making predictions
about the most likely routes of spread. The aim of these models is not to examine and quantify
the involved substeps (such as the models by Liotta et al. [8, 9, 10]), but instead they focus on the
‘global’ system dynamics.
Patterns of spread: Metastasis dynamics on networks
Understanding the patterns of spread of a particular primary tumor can help guide clinicians in
their decision making for patients. This knowledge is useful for follow up purposes in that we can
target our interrogations to the organs most likely at risk so as to minimize testing and maximize
our chances of early detection of recurrence. Further, understanding the temporal patterns of
recurrence helps us to structure our follow up schedule and to understand when to employ the
greatest vigilance, as early detection of recurrence gives the best chance of successful salvage therapy.
This temporal aspect of metastatic spread was captured in a model by Chen et al. [45], which
made use of a large database of Medicare claims. The data were such that, for each patient with a
primary tumor, a temporal sequence of metastatic events labeled according to anatomical location
were recorded. The authors analyzed the data by calculating a time-dependent hazard as a function
of the primary and metastatic site, and could observe how, given a primary in a certain location, the
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risk of developing certain metastatic lesions developed over time. They also formulated a statistical
model with the ability to predict the location of the primary tumor given a sequence of metastatic
sites, and the reverse: given a certain primary, predicting the most typical sequence of metastatic
sites. The accuracy of the above predictions is, however, not yet of a quality that makes them a
clinically relevant tool (the true positive rate of primary site prediction was 51 %), although the
study shows the potential of this kind of temporal data when mixed with a network based approach.
In another effort to better understand the patterns and timing of metastasis, Newton et al. built
and analyzed a MC model of metastatic patterns of primary lung cancers [46, 47]. By focusing on
a specific cancer, rather than patterns overall, the authors hoped to be able to infer more about the
mechanisms of metastasis than simply quantifying the patterns. When building this model, they
began by constructing a network of connected organs and made the assumption that any transition
is possible as a direct step, that is: a cancer can move directly from any organ to any other organ
(the network connectivity is ‘all to all’). Once this network was built, an iterative, random method
called the Monte Carlo method [48] was used to solve for a series of transition probabilities, which
would then lead to the steady state defined by a large autopsy study of untreated patients [49].
The quantitative understanding provided by these studies goes beyond the empirical understanding
clinicians have about patterns of spread from retrospective studies, and allows for a more detailed
analysis of the parameters and the dynamics than is possible without these methods.
The most important insight gained from this approach was that certain sites, in the case of
primary lung cancer, act differently than others, and that these differences affect the metastatic
patterns of the disease as a whole. Specifically, Newton et al. [47] identify the adrenal gland and
kidney as ‘spreaders’, which, when colonized by metastases, significantly increase the probabiliy of
further organs becoming involved. They also identified regional lymph nodes, the liver and bone
as ‘sponges’, temporally suppressing metastasis in other sites when colonized.
Embedding anatomically correct connectivity
Each of the previous studies which has utilized a network-theoretic approach has assumed ‘all to
all’ connectivity. In the case of hematogenous metastasis however, there is a simple and conserved
network architecture (that of the vasculature) that significantly reduces the complexity of the
problem and further, and more importantly, offers the possibility for patient specific modeling and
prediction - something that the previous models are unable to do. Specifically, the human vascular
network can be written down very simply as a directed network which is weighted by relative blood
flow and capillary bed filtration. Scott and colleagues recently postulated a series of hypotheses
based on this anatomically informed network [50]: that the specific filtration characteristics of each
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organ, modulated by the biology of the circulating tumor cells (CTCs), would significantly affect
the half-life of CTCs in the circulation; that one could solve for metastatic patterns by knowing a
patient’s specific filtration characteristics, much like one could solve for quantities within an electric
circuit; and that treatment could be personalized, based on CTC measurements from each of the
vascular compartments, and knowledge of the primary tumor location.
Figure 6: The human vascular system represented as a network to illustrate the filter/flow per-
spective. From this perspective, several new quantities can be calculated for an individual patient
which could be used to tailor therapy in a personalized way. Specifically: η, the filtration fraction,
which is the proportion of CTCs that are able to traverse a given capillary bed; β, the shedding rate
of an individual tumor; and, the number of CTCs in the each of the three distinct compartments
(arterial, red; port venous, purple; and, systemic venous, blue). A knowledge of each of these could,
for an individual patient, be used to better understand the individual’s risk of metastatic spread.
In a subsequent theoretical work, Scott et al. examined the self-seeding hypothesis [51] and
showed that direct self-seeding (i.e. the primary tumor shedding cells that directly returned to
the primary), which they dubbed ‘primary seeding’, was many orders of magnitude less likely
than ‘secondary seeding’, the process by which cells from the primary metastasize to a secondary
location, grow and then re-shed progeny into the vasculature which then return to the primary. This
17
distinction, while difficult or currently impossible to measure in the clinic, is of chief importance,
as it suggests that there are levels of detail about extant disease that are not captured in the
previous models. Specifically that the direct organ-organ ‘transitions’ that were suggested by
Newton et al. [47] could instead be meta-phenomena reflecting more than one transition, meaning
that information could be missed concerning the location of metastatic colonies.
While we learn about the population-level propensity and temporal dynamics of spread from
the models of Chen [45] and Newton [46, 47], what is lacking is a framework by which these models
could be applied to an individual patient. In order to make these models applicable to individual
patients, and not just more accurate statements about population level data, we have to be able
to tie them to clinical measurements. While the model of Scott and colleagues is based on a highly
heterogeneous selection of experiments [51], the underlying framework is one that can be utilized
in a patient-specific manner, a non-genetic application of the concept of ‘personalized medicine’.
Specifically, measurements of CTCs could be taken from the individual compartments (arterial,
venous and portal venous, respectively, red, blue and purple in Figure 6) and used to infer the
existence of subclinical metastatic disease. This information would provide a better understanding
of the overall tumor burden and would allow for clinical trials to test the utility of organ directed
therapy or localized therapies, depending on the patient specific clinical data.
The way forward: communication and iterative multi-disciplinary
science
Mathematical models have several roles to play in the clinical and biological sciences. The models
presented in this review have highlighted a disparate set of these roles, including generation of
novel hypotheses, explanation of phenomena which could not be described with existing, ‘cartoon’
models, and prediction of patterns of spread. We have specifically discussed a number of models
of the metastatic process which lend insight to several different aspects of the process. These
insights include: the dynamics of the emergence of metastatic potential, the distribution of size of
metastases through time, the possible mechanisms responsible for tumor dormancy, the patterns
of spread of primary tumors, and possible mechanisms driving these patterns.
These theoretical models never stand alone in the scientific process, but they do represent an
underutilized tool in the biological sciences, and particularly in the study of metastasis. Metastasis
remains the most important, lethal, and enigmatic part of cancer, and while we have been ‘waging
war’ against this disease for nearly 50 years, our progress has been limited. Indeed, the limited scope
of this review, which covers all of the theoretical work, to our knowledge, in this critical component
18
of cancer progression, highlights the dire need for more work in this area. More and more we are
finding that scientists working alone are not able to make as much progress as they could working
together - and indeed this has been the case in metastasis. Going forward, scientists from disparate
fields, including the mathematical/theoretical disciplines, must open and foster dialogues between
one another, for if we aim to understand, and therefore interrupt, this complex and non-linear
process, we have to work integrate and work together [52].
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